[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515766":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":39,"responsibleParty":52,"collaborators":54,"id":62,"slug":37,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":37,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":37,"overallStatus":41,"whyStopped":37,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High Dose (25mg)","EXPERIMENTAL","PEX010 (Oral Psilocybin), 25mg; single dose administered 24hrs prior to first of 5 weekly MET sessions",[13],"Drug: Psilocybin",{"label":15,"type":16,"description":17,"interventionNames":18},"Low dose (1mg)","ACTIVE_COMPARATOR","PEX010 (Oral Psilocybin), 1mg; single dose administered 24hrs prior to first of 5 weekly MET sessions",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Psilocybin","Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing",[9,15],[26,27],"magic mushrooms","PEX010",[29],{"name":30,"affiliation":5,"role":31},"Leah Mayo, PhD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Kaitlin O'Grady","CONTACT","587-893-0257",null,"pactlab@ucalgary.ca",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":37},"RECRUITING","Calgary","Alberta","T2N 4Z6","Canada",{"type":47,"coordinates":48},"Point",[49,50],-114.08529,51.05011,{"lat":50,"lon":49},{"type":53,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[55,57,59],{"name":56,"class":6},"Johns Hopkins University",{"name":58,"class":6},"University of Maryland",{"name":60,"class":61},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100515766",false,"NCT05995769","Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder","Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial","PAP-AUD","Inclusion Criteria:\n\n* Meets DSM-5 AUD criteria of at least moderate severity\n* Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days\n* Desire to decrease alcohol consumption\n* Limited lifetime hallucinogen use\n\nExclusion Criteria:\n\n* Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months\n* Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis\n* Active suicidal ideation or serious attempt within past 3 years\n* Currently pregnant, nursing, or trying to become pregnant\n* Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test","ALL","22 Years","65 Years",{"count":73,"type":74},128,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).",[80,81],"Alcohol Use Disorder","Alcoholism","2024-05-06",{"date":84,"type":85},"2024-05-07","ACTUAL",{"date":87,"type":85},"2024-03-20",{"date":89,"type":74},"2027-10-01",{"name":5,"class":6},1]